Antidepressant Medicine Use and Risk of Developing Diabetes During the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
- Richard R. Rubin, PHD1,2,
- Yong Ma, MS3,
- Mark Peyrot, PHD1,4,
- David G. Marrero, PHD5,
- David W. Price, MD6,7,
- Elizabeth Barrett-Connor, MD8,
- William C. Knowler, MD, DRPH9 and
- for the Diabetes Prevention Program Research Group*
- 1Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland;
- 2Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland;
- 3Biostatistics Center, The George Washington University, Rockville, Maryland;
- 4Department of Sociology, Loyola University of Maryland, Baltimore, Maryland;
- 5Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana;
- 6Department of Family Medicine, University of Colorado Denver School of Medicine, Denver, Colorado;
- 7Institute for Health Research, Kaiser Permanente, Denver, Colorado;
- 8Department of Family and Preventative Medicine, University of California, San Diego, La Jolla, California;
- 9National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.
- Corresponding author: Richard R. Rubin, .
OBJECTIVE To assess the association between antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS).
RESEARCH DESIGN AND METHODS DPP/DPPOS participants were assessed for diabetes every 6 months and for antidepressant use every 3 months in DPP and every 6 months in DPPOS for a median 10.0-year follow-up.
RESULTS Controlled for factors associated with diabetes risk, continuous antidepressant use compared with no use was associated with diabetes risk in the placebo (adjusted hazard ratio 2.34 [95% CI 1.32–4.15]) and lifestyle (2.48 [1.45–4.22]) arms, but not in the metformin arm (0.55 [0.25–1.19]).
CONCLUSIONS Continuous antidepressant use was significantly associated with diabetes risk in the placebo and lifestyle arms. Measured confounders and mediators did not account for this association, which could represent a drug effect or reflect differences not assessed in this study between antidepressant users and nonusers.
↵* A complete list of the members of the DPP/DPPOS research group can be found in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc10-1033/DC1.
The opinions expressed in this study are those of the investigators and do not necessarily reflect the views of the funding agencies.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Received June 1, 2010.
- Accepted August 21, 2010.
- © 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.